Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
NHS Blood and Transplant, Oxford, UK.
Anaesthesia. 2020 Apr;75(4):479-486. doi: 10.1111/anae.14989. Epub 2020 Feb 9.
Cell salvage is an important component of blood management in patients undergoing revision hip arthroplasty surgery. However concerns regarding efficacy and patient selection remain. The aims of this study were to describe intra-operative blood loss, cell salvage re-infusion volumes and red blood cell transfusion rates for revision hip procedures and to identify factors associated with the ability to salvage sufficient blood intra-operatively to permit processing and re-infusion. Data were collected from a prospective cohort of 664 consecutive patients undergoing revision hip surgery at a single tertiary centre from 31 March 2015 to 1 April 2018. Indications for revision surgery were aseptic (n = 393 (59%)) fracture (n = 160 (24%)) and infection (n = 111 (17%)). Salvaged blood was processed and re-infused when blood loss exceeded 500 ml. Mean (SD) intra-operative blood loss was 1038 (778) ml across all procedures. Salvaged blood was re-infused in 505 of 664 (76%) patients. Mean (SD) re-infusion volume was 253 (169) ml. In total, 246 of 664 (37%) patients received an allogeneic red blood cell transfusion within 72 h of surgery. Patients undergoing femoral component revision only (OR (95%CI) 0.41 (0.23-0.73)) or acetabular component revision only (0.53 (0.32-0.87)) were less likely to generate sufficient blood salvage volume for re-infusion compared with revision of both components. Compared with aseptic indications, patients undergoing revision surgery for infection (1.87 (1.04-3.36)) or fracture (4.43 (2.30-8.55)) were more likely to generate sufficient blood salvage volume for re-infusion. Our data suggest that cell salvage is efficacious in this population. Cases where the indication is infection or fracture and where both femoral and acetabular components are to be revised should be prioritised.
在接受髋关节翻修手术的患者中,细胞回收是血液管理的重要组成部分。然而,对于其疗效和患者选择仍存在一些担忧。本研究的目的是描述髋关节翻修手术中的术中失血量、细胞回收再输注量和红细胞输血率,并确定与术中能够回收足够血液以进行处理和再输注相关的因素。数据来自 2015 年 3 月 31 日至 2018 年 4 月 1 日在一家三级中心接受髋关节翻修手术的 664 例连续患者的前瞻性队列。翻修手术的适应证为无菌性(n=393(59%))、骨折(n=160(24%))和感染(n=111(17%))。当失血量超过 500ml 时,回收的血液将被处理并再输注。所有手术的平均(SD)术中失血量为 1038(778)ml。在 664 例患者中有 505 例(76%)接受了回收血液的再输注。平均(SD)再输注量为 253(169)ml。总共有 664 例患者中有 246 例(37%)在手术后 72 小时内接受了同种异体红细胞输血。仅行股骨组件翻修(比值比(95%CI)0.41(0.23-0.73))或仅行髋臼组件翻修(0.53(0.32-0.87))的患者与同时行两个组件翻修的患者相比,生成的可再输注回收血量更少。与无菌性适应证相比,因感染(1.87(1.04-3.36))或骨折(4.43(2.30-8.55))而行翻修手术的患者生成的可再输注回收血量更多。我们的数据表明,细胞回收在该人群中是有效的。对于感染或骨折的情况,以及需要同时翻修股骨和髋臼组件的病例,应优先考虑使用细胞回收。